Shield Therapeutics plc (LON:STX – Get Free Report) shares reached a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 3.80 and last traded at GBX 3.95, with a volume of 25964117 shares. The stock had previously closed at GBX 4.40.
Shield Therapeutics Stock Performance
The company’s 50 day moving average price is GBX 6.10 and its 200-day moving average price is GBX 8.03. The stock has a market cap of £42.25 million, a P/E ratio of -1.98 and a beta of 1.76. The company has a debt-to-equity ratio of -199.87, a quick ratio of 2.16 and a current ratio of 0.90.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Further Reading
- Five stocks we like better than Shield Therapeutics
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
